Loading...
Loading...
GNLX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 272.0K |
| Gross Profit | -272.0K |
| Operating Expense | 5,307.0K |
| Operating I/L | -5,307.0K |
| Other Income/Expense | -38.0K |
| Interest Income | 4.0K |
| Pretax | -5,345.0K |
| Income Tax Expense | -38.0K |
| Net Income/Loss | -5,345.0K |
Genelux Corporation is a clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for aggressive solid tumors. Its lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus designed for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also working on V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancer.
